Clinical trials
Combination Therapy clinical trials
Below are recruiting combination therapy clinical trials, each written for real people, not researchers. We’re tracking 879 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07597629RecruitingPhase 2
SYS6023 combination therapy for advanced breast cancer
This trial tests a new drug combination (SYS6023) for advanced breast cancer that has spread or cannot be surgically removed. The treatment targets a protein called HER3, which may help stop cancer growth in patients whose cancer has progressed despite previous treatments.
Harbin, HeilonjiangAges 18 years+ - NCT07587216Recruiting
Liver Cancer Patient Database Study
This study builds a database of information from liver cancer patients treated at Tongji Hospital. Researchers will collect your medical records and treatment information to better understand liver cancer diagnosis and care over time.
Wuhan, HubeiAges 18 years+ - NCT07586904RecruitingEarly Phase 1
New Immunotherapy Combination for Advanced Melanoma
This trial tests a combination of two drugs (cadonilimab and interferon) given before surgery to treat advanced melanoma that has spread to nearby lymph nodes or one distant site. The goal is to shrink tumors and improve chances of successful surgery and long-term survival.
Xi'anAges 18–75 - NCT06734533Recruiting
Anlotinib combo for HR+ breast cancer that has spread
This trial tests a combination treatment including anlotinib for women with hormone receptor-positive breast cancer that has spread to other parts of the body and has stopped responding to standard therapies. It is for those who have already tried a CDK4/6 inhibitor and endocrine therapy.
Changsha, HunanAges 18–75 - NCT07553455Enrolling by invitationPhase 4
Vevye plus Flarex eye drops for moderate to severe dry eye
This study tests a combination of two eye drop medications (Vevye and Flarex) to see if they work better together for treating moderate to severe dry eye. If you have persistent dry eye that hasn't improved with other treatments, this trial might help you and advance treatment options.
Azusa, CaliforniaAges 18 years+ - NCT07524101Recruiting
Statin and Ezetimibe for Heart Disease and Kidney Disease
This trial tests whether taking a moderate-strength statin (cholesterol-lowering drug) plus ezetimibe (another cholesterol medicine) together helps protect the heart and kidneys in people who have both chronic kidney disease and established heart disease or stroke history.
SeoulAges 19–85 - NCT05801380Recruiting
Tracking how well a medicine works in Alzheimer’s patients
This study looks at how effective a treatment is in people newly diagnosed with mild to moderate Alzheimer’s disease. It also involves health and medication history checks and likely stool (fecal) sample collection to monitor effects.
Manila, National Capital RegionAges 65 years+ - NCT07503756RecruitingPhase 2
JS212 Combination for Untreated Metastatic Colorectal Cancer
This trial tests a new drug called JS212 in combination with other medicines for people with metastatic colorectal cancer that has not been treated before. It focuses on patients whose tumors are MSS or pMMR and aims to see if these combinations are safe and effective.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06764836RecruitingPhase 1
IMM2510 + IMM27M for advanced solid tumors
This study tests a combination of two immune-based drugs, IMM2510 and IMM27M, for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if this combination can shrink or slow the growth of cancer.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07490262RecruitingPhase 2/Phase 3
Immunotherapy combo for advanced liver cancer as first treatment
This trial tests a new combination of two immunotherapy drugs (IBI310 and sintilimab) as a first treatment for advanced liver cancer that cannot be removed by surgery. It aims to see if this combination is safe and works better than current options.
Hefei, AnhuiAges 18–75 - NCT07483554RecruitingPhase 2
IBI343 combination therapy for advanced solid tumors
This trial tests a new drug called IBI343 combined with other treatments for people with advanced solid tumors that are CLDN18.2-positive. It aims to see if the combination can help shrink or control the cancer.
Hangzhou, ZhejiangAges 18 years+ - NCT07484724RecruitingPhase 2
JS212 combination therapy for advanced esophageal cancer
This trial tests a new combination of drugs (JS212 plus another medicine) for people with advanced esophageal squamous cell carcinoma who have not had prior treatment. It aims to see if the combination is safe and effective.
Beijing, Beijing MunicipalityAges 18–75 - NCT07479485RecruitingPhase 1/Phase 2
MRG006A combo for advanced liver cancer
This trial tests a new drug combination called MRG006A for people with advanced liver cancer (hepatocellular carcinoma) that cannot be removed by surgery or treated with local therapies. The goal is to see if it helps shrink tumors or slow cancer growth.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07474727RecruitingPhase 2
Study of AMT-676 combination therapy for advanced colorectal cancer
This trial tests a new drug combination for people with advanced colorectal cancer that cannot be removed by surgery. It aims to see if the treatment can shrink tumors and help patients live longer.
Fuzhou, FujianAges 18–80 - NCT07469683RecruitingPhase 2
Combination therapy for advanced kidney cancer after first-line treatment
This trial tests a combination of two drugs (SLC-3010 and axitinib) versus axitinib alone for people with advanced clear cell kidney cancer that has progressed after initial treatment. It aims to see if the combination is safer and more effective.
SeoulAges 19 years+ - NCT06549946RecruitingPhase 1/Phase 2
Ixovex-1 injection alone or with another drug for advanced solid tumors
This trial tests an experimental injection called Ixovex-1, either alone or with another drug (pembrolizumab), for people with advanced solid tumors that can be injected. It is for those who have run out of standard options and have tumors that are not too deep inside the body.
LondonAges 18 years+ - NCT07448922RecruitingPhase 2
Study of SKB518 for advanced gynecologic cancers
This trial tests a new drug called SKB518, either alone or with other treatments, for people with advanced gynecologic cancers (ovarian, cervical, or endometrial) who have already had some treatment. It aims to see if the drug helps shrink or control the cancer.
ChongqingAges 18–75 - NCT07442006RecruitingPhase 4
Comparing diabetes combos for stable blood sugar
This trial is testing different combinations of diabetes medicines to see which one helps keep your blood sugar more steady throughout the day. It's for people with type 2 diabetes who are already taking metformin and an SGLT-2 inhibitor but still have high blood sugar.
SeoulAges 19 years+ - NCT07407504RecruitingPhase 1
Targeted therapy for cancers with a specific gene change
This trial tests an experimental drug called GenSci145, which may target cancers with a specific gene change called PIK3CA. The drug is given alone or with other treatments. The goal is to see if it can shrink tumors or slow cancer growth.
Beijing, Beijing MunicipalityAges 18–75 - NCT07414212RecruitingPhase 1/Phase 2
Testing EH-301 and NAC with Riluzole for ALS
This trial tests whether adding two supplements (EH-301 and N-acetylcysteine) to the standard ALS medicine Riluzole can help slow the disease. It is for people diagnosed with ALS within the last 18 months who still have good breathing and daily function.
San Sebastián, GuipuzcoaAges 18–75 - NCT07403721RecruitingPhase 1
Study of AMG 436 for MSI-H/dMMR Cancers
This study tests an experimental drug called AMG 436, alone or with other treatments, for people with advanced solid tumors that have a specific genetic change (MSI-H or dMMR). The goal is to see if the drug can shrink tumors and if it is safe.
Irvine, CaliforniaAges 18–99 - NCT07403201RecruitingEarly Phase 1
Combination therapy for PCOS
This trial is testing a combination treatment for PCOS. It is looking for married women who are willing to join the study.
Yogyakarta, DIYAges Up to 45 years - NCT07389824Recruiting
Acupuncture plus mesalazine for ulcerative colitis
This study tests whether adding acupuncture (using small intradermal needles) to the standard medication mesalazine improves outcomes for people with mild-to-moderate ulcerative colitis. Participants receive 12 acupuncture sessions and undergo two colonoscopies to assess the treatment's effect.
Wuhan, HubeiAges 18–75 - NCT07371663RecruitingPhase 1/Phase 2
TCC1727 combination therapy for advanced solid tumors
This trial tests a new drug, TCC1727, combined with other treatments for people with advanced solid tumors that have stopped responding to standard therapy. It aims to see if these combinations can help shrink or control the cancer.
Beijing, Beijing MunicipalityAges 18 years+
Hear when a new Combination Therapy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for combination therapy?
- Yes. Clin2 currently lists 879 recruiting combination therapy studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a combination therapy trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a combination therapy trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.